Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioAffinity Technologies, Inc. ( (BIAF) ) has shared an announcement.
On March 25, 2026, bioAffinity Technologies announced it will host the first in a series of live virtual physician roundtables exploring the integration of its CyPath® Lung diagnostic test into pulmonary practice. The inaugural session, scheduled for April 8, 2026, will feature leading pulmonologists discussing real-world cases where CyPath® Lung aided lung cancer risk assessment, management of indeterminate pulmonary nodules, and surveillance of lung cancer survivors, underscoring the test’s role in improving clinical decision-making and potentially reducing unnecessary invasive procedures.
During the webinar, physicians will present cases that range from detecting Stage 1A lung cancer, when treatment is most likely to be curative, to avoiding risky and costly interventions when CyPath® Lung indicated a low likelihood of malignancy. By providing practical guidance on incorporating this noninvasive test with reported sensitivity of 92%, specificity of 87% and accuracy of 88% in high-risk patients with small nodules, the event is positioned as a vehicle to drive clinician adoption and strengthen bioAffinity’s position in the lung cancer diagnostics market.
The most recent analyst rating on (BIAF) stock is a Sell with a $4.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.
Spark’s Take on BIAF Stock
According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.
The score is held down primarily by weak financial performance (widening losses and accelerating cash burn despite balance sheet repair). Offsetting factors include constructive technical momentum (though overbought) and a string of positive, adoption-focused corporate developments; valuation remains constrained by loss-making results and no dividend support.
To see Spark’s full report on BIAF stock, click here.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection, with an emphasis on lung disease. Its first product, CyPath® Lung, is a sputum-based Laboratory Developed Test that uses flow cytometry and proprietary AI to detect early-stage lung cancer and is marketed through its subsidiary Precision Pathology Laboratory Services to high-risk patient populations.
Average Trading Volume: 8,241,043
Technical Sentiment Signal: Hold
Current Market Cap: $21.28M
See more insights into BIAF stock on TipRanks’ Stock Analysis page.